Phase 2
N=314
Strategies To Prevent Pneumonia 2 (SToPP2)
Infections, Hospital · Ventilator-Associated Pneumonia · Mechanical Ventilation Complication
Bottom Line
View on ClinicalTrials.gov: NCT00893763 ↗Enrolled (actual)
314
Serious AEs
0.0%
Results posted
Jan 2016
Primary outcome: Primary: Development of VAP (Clinical Pulmonary Infection Score) — 4.13; 4.45 units on a scale — p=0.1763
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Pre-intubation CHX (Procedure); Control (Procedure)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of South Florida
- Primary completion
- Jun 2012
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Development of VAP (Clinical Pulmonary Infection Score) |
4.13; 4.45 | 0.1763 |
| SECONDARY Endotracheal Tube Colonization |
18.6; 17.5 | — |
| SECONDARY Serum Cytokines |
— | — |
| SECONDARY Serum Procalcitonin |
— | — |
Summary
Ventilator-associated pneumonia (VAP) is a serious complication in mechanically ventilated critically ill patients. The intervention tested in this project (swabbing the mouth with chlorhexidine before the endotracheal tube is inserted) could reduce the risk of ventilator-associated pneumonia.
Eligibility Criteria
Inclusion Criteria
- Need for intubation
Exclusion Criteria
- Pneumonia at the time of intubation
Data sourced from ClinicalTrials.gov (NCT00893763). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.